ERCC2 and colorectal carcinoma: Although some researchers have identified incomplete repair of DNA damage or of aromatic DNA adducts in the presence of ERCC2 variant alleles [42,54-58], we hypothesize that the malignant entity of the C (Glu) allele of ERCC2 Lys751Gln is responsible for poor prognosis of early relapse among CRC patients receiving similar chemotherapeutic regimens in this study.